Aims: To study the preliminary effects and safety of TACE using doxorubicin -loaded microspheres for treatment of HCC. Subjects and methods: a prospective study involved 30 HCC patients (mean tumor size: 55.8 + or - 24mm) underwent TACE using drug-loaded beads at the 108 hospital, from June 2011 to May 2012. The authors used lor 2 from 3 different sizes of DC-Beads (100-300um, 300-500um and 500-700um) loaded with 75mg doxorubicin per 1 procedure. Tumor responses were assessed at 1 month, 3 month and 6 month after the first procedure according to modified RECIST. Postembolizatioh syndrome and complications were also recorded. Results: A total 35 procedures were successful peiformed. The objective response rate according to modified RECISTwas 86.6 percent at 1 month, 66.7 percent at 3 month and 61.1 percent at 6 month follow-up. Serum AFP levels were decreased significantly after treatment. Postembolization syndrome was observed in 93.3 percent of cases but mild and recovered without any treatment. There were no case of doxorubicin -related systemic toxicities. The complication occurred in 1 cases (tumor abscess). One death occurred within 6 months follow-up due to the progression of disease but there were no case of procedure-related death. Conclusion: DC-Beads TACE is safe and effective treatment for patients with HCC.
- Đăng nhập để gửi ý kiến